Skye Bioscience, Inc. — Director's Dealing 2015

Jun 4, 2015

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Nemus Bioscience, Inc. (NMUS)
CIK: 0001516551
Period of Report: 2015-06-01

Reporting Person: INGRAM DOUGLAS S (Director, Vice Chairman)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Preferred Stock	$2.50		Common Stock (100000)		Direct
Common Stock Warrant (Right to Buy)	$5.00	2020-04-07	Common Stock (20000)		Direct

Footnotes

F1: Pursuant to a Securities Purchase Agreement dated April 7, 2015, between the Reporting Person and the Issuer, the Reporting Person acquired 100,000 shares of Series A Preferred Stock and warrants to purchase 20,000 shares of the Issuer's common stock at an exercise price of $5.00 per share in exchange for $250,000.

F2: The Series A Preferred Stock are automatically convertible in accordance with the Issuer's Certificate of Designation and Certificate of Correction, which are included as exhibits 3.1 and 3.2, respectively, to the Issuer's Form 8-K filed on April 7, 2015, and do not have an expiration date.

F3: Subject to adjustment as specified in the Issuer's Certificate of Designation, which is included as exhibit 3.1 to the Issuer's Form 8-K filed on April 7, 2015.